Although the incidence of endometrial cancer in African-American (AA) women is lower than in Caucasian (C) women, a striking racial disparity exists in endometrial cancer survival rates in the United States, with blacks having up to 30% worse survival rates than whites. Socio-demographic factors alone cannot account for this difference because differences in survival still occur when analyses are adjusted for black and white women by stage and by biologically aggressive (i.e., Type II) endometrial tumors. Uterine serous papillary carcinoma (USC), represents the most aggressive histologic subtype of endometrial cancer. This variant of endometrial carcinoma is up to three fold more frequent in AA women when compared to C women. On the basis of our recently published data on the genetic landscape of USC suggesting that genetic and biologic factors may underlie the racial disparity in survival rates and with the ultimate goal to develop novel, more specific and more effective treatment modalities for the diagnosis and therapy of USC so common in AA women, we propose the following:
Aim 1 : Identify through whole exome sequencing driver mutation candidates, loss of heterozygosity (LOH) patterns and copy number variations (CNV) in 200 USC samples and use bioinformatics strategies to perform a systematic assessment of genetic differences between AA vs C tumors, Aim 2: Evaluate miRNAs and mRNA expression differences in USC from AA and C and perform downstream analysis of pathways influencing disease in different groups of USC (i.e., c-erbB2+ vs negative and PIK3CA and CCNE1 mutants vs wild type) and Aim 3: Evaluate the biochemical properties of a subset of novel PIK3CA mutations and validate the c-erbB2/PIK3CA and CCNE1 pathways as novel targets for USC treatment using primary USC cell lines and targeted agents including trastuzumab and T-DM1 (i.e., mAbs targeting c-erbB2), AZD8055, GDC-0980 and CYC065 (i.e., a mTOR/PI3K/CDK inhibitors) in in vitro and in vivo assays. This proposal encompasses the first integrated analysis of genomic differences in USC developed by AA when compared to C women as well as the validation of the currently identified differentially expressed genes harboring key driver mutations as novel targets for USC therapy in minority. Relevance Definition and functional validation of key driver mutations and downstream signaling pathways differentially active in AA women harboring USC may be used to guide novel, highly effective targeted therapies against these highly aggressive tumors and, therefore, may have immediate clinical relevance on minority health.
Type II endometrial tumors such as uterine serous carcinoma (USC) are more commonly diagnosed in AA women when compared to C women, suggesting a genetic predisposition in black women to develop these biologically aggressive neoplasms. This proposal is designed to perform the first comprehensive analysis of genomic differences in USC developed by AA women when compared to C women. We will search for driver gene mutations, loss of heterozygosity (LOH) and copy number variations (CNV) and identify miRNAs and genes highly differentially expressed in USC developed by AA women when compared to C women. These studies will provide essential information for a better understanding of the genetic cause of the disparity in frequency of this diagnosis in AA women as well as the molecular basis responsible for the unfavorable prognosis more frequent in AA women relative to C women. Finally, our results will provide essential information for the development of USC-specific therapies for preventing progression of advanced/recurrent disease after conventional surgery and chemotherapy.
|Nicoletti, Roberta; Lopez, Salvatore; Bellone, Stefania et al. (2015) T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. Clin Exp Metastasis 32:29-38|
|English, Diana P; Bellone, Stefania; Schwab, Carlton L et al. (2015) Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Cancer 121:403-12|
|Lopez, Salvatore; Schwab, Carlton L; Cocco, Emiliano et al. (2014) Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecol Oncol 135:312-7|
|Schwab, Carlton L; English, Diana P; Roque, Dana M et al. (2014) Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecol Oncol 135:142-8|